Five of the 32 patients had subnormal serum B12 levels. Reduction in the serum B12 level was related to the reduction in the normal circulating immunoglobulins and occurred despite normal B12 absorption. Possible explanations for this finding are discussed.
Subnormal serum vitamin B12 concentrations have been reported in patients with multiple myeloma by a number of authors (Mollin and Ross, 1952; Mandema, 1956; Mandema, Faber, de Vries, and Nieweg, 1956; Killander and Larsson, 1962; Larsson, 1962; Forshaw, 1963; Hansen, 1964) . In some ofthese patients megaloblastic anaemia was also observed and in the patients of Mandema (1956) , in two patients of Larsson (1962) , and in the patient of Forshaw (1963) the anaemia responded to large doses of vitamin B12. The anaemia in another patient of Larsson (1962) and the patient of Bichel (1964) responded to liver therapy.
Nonetheless, true Addisonian pernicious anaemia appears to be rare in myeloma and it has only been established by the demonstration of histamine-fast achlorhydria associated with malabsorption of vitamin B12 corrected by intrinsic factor in three patients (cases 2,3, and 5 of Larsson, 1962) . The cause of subnormal serum B12 concentrations in patients with myeloma without pernicious anaemia is uncertain. It has been suggested that they are due to malabsorption of vitamin B12 associated with bacterial contamination of the small intestine (Larsson, 1962) or to excess B12 utilization by the tumour (Mandema et al., 1956 Larsson, 1962; van Dommelen, Olie, and Slagboom, 1964) .
The present study was undertaken to determine the incidence, severity, and cause of B12 deficiency in patients with multiple myeloma. Since megaloblastic anaemia in other conditions in which there is proliferation of primitive tissue is almost invariably due to folate deficiency (Swendseid, Swanson, Meyers, and Bethell, 1952; Girdwood, 1953) , the incidence and pathogenesis of folate deficiency was investigated in the same group of patients and this paper reports the results of both studies.
PATIENTS STUDIED Thirty-two randomly selected patients with myeloma were studied. Their ages ranged from 42 to 81 (mean 67 years) and they included 17 males and 15 females. All the patients were investigated while in hospital for investigation or treatment.
In each patient, the diagnosis was made because the patient showed clinical and/or radiological evidence of bone lesions of the myeloma type, abnormal and increased numbers of plasma cells in the bone marrow, a characteristic narrow 'monoclonal' band on electrophoresis of the serum proteins and/or Bence-Jones proteinuria. Ten patients were studied at the time myeloma was first diagnosed, and in the remaining 22 (Drivsholm, 1964) .
For the same serum concentration, therefore, YA protein has a faster turnover (estimated as 10-8 % of the total pool) than YG protein (estimated as 6% of the total pool). In order to compare our patients, we have arbitrarily considered them all to be 71 kg. in weight, with a plasma volume of 50 7 ml. per kg., with the plasma containing 71% of the total pool of myeloma globulin (averages of availabledatainmyeloma patients, Gabuzda, 1962) . Thus, fora given serum concentration of myeloma globulin, M g. per 100 ml., the total pool would be M x 71 x 50-7 x 100°= 50 7 M g., and for patients in equilibrium, the average daily productions of YA would be 10-8% of 50-7M = 5 5 Mg., andofyG6% of 50-7M = 30 Mg.
In order to obtain the total daily M protein production, the daily Bence-Jones protein loss in the urine was measured, corrected to 71 kg. from the patient's body weight, and added to the production of M protein, calculated above.
It is recognized that this calculation only gives an approximate value since plasma and total body pools and the half life of the plasma proteins all show individual variation. Nevertheless, this variation is mostly less than ± 25% of the taken means. patients were anaemic at the time of the present studies (Table I ). There was no direct correlation Table II . In only one patient was B12 absorption reduced to the range found in pernicious anaemia, and in this patient (case 13) the increased absorption with intrinsic factor was suboptimal. In four patients with only slightly reduced B12 absorption, the absorption with intrinsic factor was normal. The absorption of radioactive B12 was within the normal range in the three patients with subnormal serum B12 levels and in the other four patients tested. 
LOSS OF NORMAL HUMORAL IMMUNITY
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PATHOGENESIS OF THE SUBNORMAL SERUM FOLATE LEVELS
In contrast to the finding with serum B12 levels, there was a moderately good inverse correlation between the calculated daily paraprotein production of the patients and their serum folate concentrations, the patients with the greatest paraprotein production having the lowest serum folate levels (Fig. 4) Begemann Sandkuhler, 1951; Mandema, 1956; Reisner, 1958; Forshaw, 1963) that megaloblastic changes are frequently present in patients with myeloma. In addition, they show that the predominant cause of these changes is folate deficiency. In an occasional patient studied here folate deficiency was sufficiently severe to contribute to anaemia but in the majority of the folate-deficient patients there was either no response to folic acid or the deficiency was too mild to be a cause of anaemia. Since there is a theoretical objection to giving folic acid to patients with malignant disease because it might increase the rate of growth of the tumour, it is probably advisable to reserve folic acid therapy in myeloma to patients who have clear evidence of severe deficiency and in whom anaemia or possibly thrombocytopenia are important features. The main cause of folate deficiency in myeloma is likely to be increased folate utilization by the tumour. This is supported by the present finding of the lowest serum folate levels in the patients with the greatest paraprotein production. The latter may well be roughly related to the mass of tumour cell present (Nathans, Fahey, and Potter, 1958) . Reduced dietary folate intake might also contribute to the deficiency in some of the patients since they almost invariably have anorexia.
The low serum B12 levels in myeloma are more unexpected and also more difficult to explain. Subnormal serum B12 levels are not usually found in generalized malignant diseases in which, in the absence of gastrointestinal involvement, serum B12 levels are normal or elevated (Mollin and Ross, 1957) .
A few of the patients with myeloma and B12 deficiency reported by other authors had frank pernicious anaemia, but, as Larsson (1962) suggests, this may be a chance association. In the majority of patients with myeloma and subnormal serum B12 levels, pernicious anaemia is not present, and in some, as in cases 1, 7, and 8 here, B12 absorption is normal. This is an unusual finding. Subnormal serum B12 levels with normal B12 absorption occur in vegans (Wokes, Badenoch, and Sinclair, 1955) , in some patients with severe megaloblastic anaemia due to folate deficiency (Mollin, Waters, and Harris, 1962) , and in infants born to B12-deficient mothers (Lampkin, Shore, and Chadwick, 1966) . It has also been reported in a single patient with B12-dependent anaemia apparently due to defective plasma binding ofB12 (Horrigan and Heinle, 1952) and it occurs rarely after partial gastrectomy (Deller and Witts, 1962) . Killander and Larsson (1962) suggested that the subnormal B12 levels in myeloma weremainly dueto excess utilization of B12 by the tumour, since in their study the lower serum B12 levels occurred in the patients with the highest serum concentrations of myeloma protein. The present results do not confirm this. Rather they show that the reduction in serum B12 level is related to the reduction in the normal circulating immunoglobulins. The three patients of Killander and Larsson all had yG myelomata and, although the authors do not comment on this, are therefore likely to have had severe immuneparesis (Hobbs, Slot, Campbell, Clein, Scott, Crowther, and Swan, 1966) . It is of interest that B12 deficiency is not infrequent in patients suffering from hypogamma- (Klayman and Brandborg, 1955; Larsson, Hagelquist, and Coster, 1961; Gibbs and Pryor, 1961; Lee, Jenkins, Hughes, and Kazantzis, 1964) . Although Meyer, Bertcher, Cronkite, Suarez, Miller, Mulzac, and Olivarreta (1961) could not detect any reduction in the B12-binding capacity in vitro of serum from patients with myeloma, this does not exclude reduction in the concentration of the endogenous B12-binding protein in this condition. The relation between serum B12 level and degree of immuneparesis found here could be explained if the low serum B12 levels were due to a reduction in this endogenous serum B12-binding protein (an a globulin) in parallel to the reduction in immunoglobulins.
Five patients with normal serum B12 levels had subnormal serum B12 absorption but in only one of them was the absorption as low as in pernicious anaemia. In all five absorption was significantly improved by intrinsic factor. These findings suggest reduced secretion of intrinsic factor in these patients but this is not an uncommon finding in patients of a similar age group. In Forshaw's (1963) patient whose serum B12 level was just subnormal (120,u,ug. per ml.), B12 absorption was at the lower limit of normal and improved significantly with intrinsic factor. In this patient, however, free gastric acid was present and a gastric biopsy was normal.
The present studies lend no support to the theory that B12 deficiency in myeloma is due to bacterial contamination of the small intestine. In none was there severe reduction in B12 absorption when this was tested with added intrinsic factor.
